Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares Core High Dividend ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while iShares Core High Dividend ETF trades at $27.93. The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | HDV | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $28.09 |
52-Week Low | $20.06 | $23.63 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
HDV trades at $27.70, down 1.21% on the day, with a bullish technical signal driven by moving averages and neutral oscillators. The ETF focuses on high-quality, high-dividend U.S. stocks, currently yielding around 3.0%, and has outperformed the S&P 500 over five years with lower volatility. Recent news highlights its defensive sector tilt toward healthcare and energy, though this introduces oil price sensitivity.
The outlook for HDV is favorable for income-focused investors seeking stable dividends and lower market correlation, but risks include sector concentration in energy and competitive pressure from lower-cost dividend ETFs. Long-term performance hinges on sustained dividend growth from its quality-focused portfolio amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
